Ultragenyx Pharmaceutical Inc. reaffirmed earnings guidance for the year 2024. For the full year 2024, the company reaffirms: Total revenue in the range of $500 million to $530 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
40.12 USD | -3.41% | -2.37% | -16.35% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.35% | 3.45B | |
+8.21% | 115B | |
+13.10% | 107B | |
-13.63% | 22.31B | |
-3.99% | 21.6B | |
-5.69% | 18.23B | |
-39.93% | 17.62B | |
+7.36% | 14.26B | |
+33.53% | 12.37B | |
-28.37% | 8.28B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024